Calidi Biotherapeutics, a clinical-stage biotech developing allogeneic stem cell-based platforms for oncolytic virus immunotherapies, has been awarded a $3.1m grant from the California Institute for Regenerative Medicine (CIRM).
ExPLoRNA Therapeutics, a Polish biotech developing mRNA vaccines and therapeutics with improved translational efficiency, has received funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology.
Rani Therapeutics, which is aiming to orally deliver the osteoporosis drug, PTH, for the first time, has shared positive clinical data from part two of its Phase 1 trial for RT-102, its RaniPill capsule.
Curamys, a South Korean biotech developing cell and gene therapy using cell fusion technology to treat rare intractable diseases, has signed a strategic platform licensing agreement with US tech developer, MaxCyte.
Vaxxas has completed a financing round which raised US$23m (A$34m) in new funds: allowing the company to progress multiple vaccine programs in the clinic and ramp up manufacturing capabilities towards commercial scale.
Valneva is pushing forward with its live-attenuated, single-shot vaccine candidate, VLA1553, for chikungunya, a mosquito-borne viral disease for which there are no preventive vaccines or effective treatments available.
The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer’s will require drugs that do more than clear amyloid plaques, says the Alzheimer’s...
Touchlight has secured a grant from the Bill & Melinda Gates Foundation for a research program aimed at demonstrating that its enzymatically produced novel DNA format can support a rapid, scalable, durable, and thermostable vaccine solution for future...
BigHat Biosciences, a US biotech with a machine learning-guided antibody discovery and development platform, has announced a collaboration with Merck to apply its technology to design candidates for up to three drug discovery programs.
The Centre for Advanced Therapies Manufacturing Training, which is based at the University of Birmingham in the UK, today announced a program aimed at growing the industry’s skills base for advanced cell and gene therapy manufacturing.
A new experimental mRNA-based vaccine could give a baseline level of immune memory against diverse flu strains: and thus might serve one day as a general preventative measure against future flu pandemics, according to researchers.